• Executed fifth licensing agreement with Everest Medicines for DMX-200 in Asia
• Aggregate value of licensing agreements now approximately A$1.9 billion
• ACTION3 Phase 3 study remains appropriately powered to demonstrate treatment effect
• Acquired DMX-652, a Phase 2-ready asset for acute kidney injury
• Secured A$10 million non-dilutive funding

Dimerix Limited, a clinical-stage biopharmaceutical company, reported its quarterly activities and financials. Key highlights include the execution of a fifth licensing agreement with Everest Medicines for DMX-200 in Asia, increasing the total potential value of licensing agreements to approximately A$1.9 billion. The company also secured A$10 million in non-dilutive funding to support pipeline expansion and clinical development. Dimerix continued to progress the ACTION3 Phase 3 study for DMX-200 in focal segmental glomerulosclerosis (FSGS), with the study remaining appropriately powered. Additionally, Dimerix acquired DMX-652, a Phase 2-ready asset for acute kidney injury, expanding its pipeline. The company is now funded through the completion of the ACTION3 Phase 3 trial and the initiation of the Phase 2 trial for DMX-652.